Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21946654 | 0.88 | CRBN (0.53) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL25847908 | 0.86 | ALDH1A1 (0.36) | CRBNDDB1ALDH1A1TDP1 | |
| SCHEMBL29346446 | 0.83 | CRBN (0.45) | CRBNDDB1PARP1IKZF3ALDH1A1 | |
| SCHEMBL20436926 | 0.81 | DDB1 (0.35) | CRBNDDB1 | |
| SCHEMBL24891103 | 0.78 | CRBN (0.47) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20437025 | 0.78 | CRBN (0.47) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29346443 | 0.77 | PARP1 (0.39) | PARP1ALDH1A1NSD3 | |
| SCHEMBL23593989 | 0.74 | CRBN (0.44) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24891031 | 0.74 | CRBN (0.45) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24891065 | 0.74 | CRBN (0.45) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142629-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142629-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | IRAK1, IRAK2, IRAK4 | CRBN 324/4885DDB1 661/4885PARP1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.